Browsing articles from "November, 2022"

HR Resources

 //  No Comments

HR Resources (PDF LINK)

  • The American Academy of Ophthalmology’s website has a section devoted to practice management, which includes HR resources. They provide a video library and a collection of forms among other helpful tools.
  • The American Academy of Ophthalmology has a practice management affiliate, The American Academy of Ophthalmic Executives (AAOE), with membership benefits that include resources and a supportive network to help in all aspects of business operations, including HR.
  • The Society for Human Resource Management (SHRM) is professional organization for HR. Members get most of their benefits through the society’s website, where they can access legislative news, helpful articles, and HR-related forms and templates.
  • State Chambers of Commerce often offer HR resources. For example, CalChamber (the California Chamber of Commerce) created HRCalifornia to help members navigate and comply with California’s complex employment laws.
  • Private Equity Firms may provide the HR function for their members or offer assistance.
  • Human Resource consulting firms offer comprehensive HR services to their clients including guidance and support with specific responsibilities such as recruiting.
  • There are law firms that specialize in employment law. In addition to providing legal advice, they frequently offer training or related topics and have insights into best practices.

If you have questions about these recommendations, or would like to have a confidential risk management consultation, please contact us at riskmanagement@omic.com or 1-800-562-6642, enter 4 for Risk Management.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protected: ROP Update 2022

,  //  Enter your password to view comments.

This content is password protected. To view it please enter your password below:

Bevacizumab Biosimilars

 //  No Comments

November 2, 2022 


Dear OMIC Insureds: 

An increasing number of ophthalmologists treating retinal conditions with intravitreal anti-VEGF agents are being asked by health systems and hospitals to utilize bevacizumab biosimilar drugs. Both the AAO (2022) and CMS (2021) have issued statements recommending against the use of off-label bevacizumab biosimilars to treat ocular conditions due to insufficient data regarding long-term efficacy and safety profiles. OMIC supports these statements and strongly recommends against the use of bevacizumab biosimilar drugs for intravitreal injection, as well as off-label use of all biosimilars for the treatment of ROP until further clinical data becomes available.

If you have questions about this topic or would like to have a confidential risk management consultation, please email riskmanagement@omic.com or 1-800-562-6642, enter 4 for OMIC Risk Management.


Sincerely,


Michael C. Tigani, MD
Chair, OMIC Risk Management Committee




Six reasons OMIC is the best choice for ophthalmologists in America.

Leader in the industry.

A-rated by AM Best, OMIC is consistently ranked among the top malpractice insurance companies in America for financial stability. No other carrier has matched OMIC's consistent financial performance with regard to both combined, operating, and surplus ratios, the most relevant financial measurements for an insurance carrier.

61864684